Sling Therapeutics
PrivateLast Round
Series C
Sep 16, 2026
Est. Valuation
$140M
Total Funding Raised
$158M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Sling Therapeutics is a biopharmaceutical company focused on developing oral small molecule linsitinib to provide innovative treatment options for patients in the ophthalmology, endocrinology, and rare disease sectors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sling Therapeutics Comparables
Compare Sling Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Khartis Therapeutics | 86% | |
| Ethyreal Bio | 83% | |
| VelaVigo | 81% |
Sling Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 16, 2026 | ||||
| Series A | Jun 13, 2022 |
Sling Therapeutics Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 16, 2026
$123M round led by Forbion
- Jul 26, 2026
Monthly visitors increased 47% MoM.
Recent news
Latest coverage and updates
- hiresSep 16, 2026
Sling Therapeutics, Inc. hired François Beaubien as board of directors on Sep 16th '26.
- receives_financingSep 16, 2026
Sling Therapeutics, Inc. received financing of $123M in Series C on Sep 16th '26.
- hiresSep 16, 2026
Sling Therapeutics, Inc. hired Regina Salvat as board of directors on Sep 16th '26.
Sling Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access